Navigation Links
InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
Date:9/14/2009

LOS ALTOS, Calif., Sept. 14 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Linda Slanec Higgins, PhD has been named Chief Operating Officer. Since late 2007, Dr. Higgins has served as InteKrin's Chief Scientific Officer after joining the Company earlier that year. Over the past two years, Dr. Higgins has had increasingly broad operational and strategic responsibility in key areas including CMC and dosage form development, Regulatory Affairs, Corporate Development and Product Development.

"Linda's contributions to InteKrin's progress have been extraordinarily impactful and decisive," said Denny Lanfear, InteKrin Chief Executive. "By large measure, her leadership and capabilities have allowed us to move INT131 forward in many dimensions over the past two plus years and successfully surmount the considerable challenges confronting privately funded development stage companies."

"I am very pleased to have contributed to the advancement of this important therapeutic," said Dr. Higgins. "We at InteKrin look forward to completing our Phase 2b efforts and moving on into Phase 3."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
2. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
3. InteKrin Therapeutics Announces $20 Million Series C Financing
4. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
5. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
6. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
7. Oxygen Biotherapeutics, Inc. Posts Latest Blog by CEO Chris Stern
8. Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference
9. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
10. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
11. Reportlinker Adds Autoimmune Disease Therapeutics Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 18, 2017 , ... Western University of Health Sciences ... to launch the University’s new Center for Innovation on Wednesday, September 6, 2017. , ... Lecture Hall 1, followed by a technology exhibition from 1 to 3 p.m. showcasing ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press ... mothers. These illustrations show the diversity of the breastfeeding mothers, using bright ... range of sizes. These illustrations are also available on tote bags, notepads, smartphone ...
(Date:8/18/2017)... Bangkok, Thailand (PRWEB) , ... August 19, 2017 ... ... and Business, Tourism Authority of Thailand presided over the Amazing Thailand Health and ... innovation in Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and ...
(Date:8/18/2017)... ... 18, 2017 , ... August 18, 2017 — Mediaplanet today ... active, healthy lifestyles and highlighting the importance of proactive eye and ear health ... shares the latest innovations in hearing aid technology. , According to the ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a family ... in North-Central West Virginia, is embarking on a cooperative charity effort with the ... , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short ... to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:7/31/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named ... by Crain,s Detroit Business . ... by three-year revenue growth. This year,s edition measures growth from ... view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... triumph," said Phil Hagerman , CEO and chairman of ...
(Date:7/28/2017)... Mich. , July 28, 2017 EnvoyHealth, a ... to pilot a program for CleverCap LITE, a technology ... CMT strives to deliver innovative health technology solutions and ... CleverCap LITE offers ... compact, high-tech bottle cover: ...
Breaking Medicine Technology: